You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 5,945,416


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,945,416
Title: Method for treating pain
Abstract:The present invention provides a method for treating pain using a composition comprising olanzapine and Drug Useful in the Treatment of Pain.
Inventor(s): Shannon; Harlan E. (Carmel, IN), Womer; Daniel E. (Thornton, CO)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:08/823,461
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

United States Patent 5,945,416: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 5,945,416, titled "Method for treating pain," is a significant patent that outlines a novel approach to pain management using a specific composition. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background and Invention Overview

The patent, filed as US08/823,461, was granted on August 31, 1999. It describes a method for treating pain using a composition that includes olanzapine, a drug commonly known for its use in treating psychiatric disorders such as schizophrenia and bipolar disorder. The invention leverages the analgesic properties of olanzapine to provide a new therapeutic option for pain management[1].

Scope of the Patent

The scope of the patent is defined by its claims, which are the legally binding descriptions of the invention. Here, the claims focus on the specific composition and the method of using olanzapine for pain treatment. The patent scope includes:

  • Composition Claims: The patent claims a composition comprising olanzapine and another drug useful in the treatment of pain. This composition is designed to be administered in a manner that optimizes pain relief.
  • Method Claims: The method claims describe the process of administering the composition to treat pain. This includes the dosage, frequency, and route of administration.

Claims Analysis

The claims of the patent are crucial as they define the boundaries of the invention and what is protected by the patent.

  • Independent Claims: These claims stand alone and define the broadest scope of the invention. For example, Claim 1 might describe the composition and its use in treating pain.
  • Dependent Claims: These claims build upon the independent claims and provide more specific details. For instance, a dependent claim might specify a particular dosage or administration route.

Patent Landscape

Understanding the patent landscape is essential to grasp the context and significance of US 5,945,416.

  • Prior Art: The patent landscape includes prior art that was considered during the examination process. This includes other patents and publications related to pain treatment and the use of olanzapine.
  • Competing Patents: Other patents in the field of pain management and psychiatric treatments are part of the landscape. These patents may use different compositions or methods, but they are relevant in understanding the competitive environment[3].

Inventorship and Ownership

Determining the true and only inventors is a critical aspect of patent law. For US 5,945,416, the inventors listed are those who conceived the idea and reduced it to practice. The ownership of the patent can change over time through assignments or licensing agreements[2].

Economic and Market Impact

The value of a patent like US 5,945,416 can be significant, especially if it offers a novel and effective treatment for a common condition like pain.

  • Monetary Value: The monetary value of patents can vary widely. For example, major tech companies have paid billions of dollars for patent portfolios, highlighting the potential economic impact of a single patent[4].
  • Market Dominance: A patent that offers a unique solution can provide its owner with a competitive edge in the market. This can lead to increased market share and revenue.

Legal Status and Expiration

As of the current date, the legal status of US 5,945,416 is expired due to fee-related issues. This means that the patent is no longer enforceable, and the invention is now in the public domain.

Impact on Research and Development

Expired patents like US 5,945,416 can still influence research and development in the field.

  • Public Domain: With the patent expired, the information and methods described are now freely available for use by anyone. This can stimulate further research and innovation in pain management.
  • Reference Point: The patent can serve as a reference point for new inventions, helping researchers to build upon existing knowledge.

Case Studies and Analogies

To understand the broader implications, let's consider analogous situations:

  • Google-Motorola Deal: Google's acquisition of Motorola Mobility for $12.5 billion, which included 24,500 patents, highlights the strategic importance of patent portfolios. Similarly, a patent like US 5,945,416, even if expired, can be a valuable piece of intellectual property in the context of broader research and development strategies[4].

Challenges and Controversies

Patent disputes and challenges are common, especially in highly competitive fields.

  • Inter Partes Review: The case of Arbutus Biopharma Corporation vs. Moderna Therapeutics illustrates the complexities of patent disputes. Such challenges can impact the validity and enforceability of patents, even after they have been granted[5].

Key Takeaways

  • Novel Composition: US 5,945,416 describes a novel composition using olanzapine for pain treatment.
  • Expired Status: The patent is currently expired due to fee-related issues.
  • Economic Impact: The patent could have significant economic value if it were still enforceable.
  • Research Influence: The patent's expiration makes its information publicly available, potentially influencing future research.
  • Legal Considerations: Patent disputes and challenges can affect the validity and enforceability of patents.

FAQs

What is the main subject of US Patent 5,945,416?

The main subject of US Patent 5,945,416 is a method for treating pain using a composition that includes olanzapine.

Who are the inventors listed on the patent?

The patent does not specify the inventors in the provided sources, but they would be those who conceived the idea and reduced it to practice.

What is the current legal status of the patent?

The patent is currently expired due to fee-related issues.

How does the patent impact research and development in pain management?

The patent's expiration makes its information publicly available, which can stimulate further research and innovation in pain management.

What is the economic value of a patent like US 5,945,416?

The economic value can be significant, as seen in other patent deals where companies pay millions or even billions of dollars for patent portfolios.

Sources

  1. US5945416A - Method for treating pain - Google Patents
  2. Determining Inventorship for US Patent Applications
  3. Patent Claims Research Dataset - USPTO
  4. The value of a patent - Perpetual Motion Patents
  5. ARBUTUS BIOPHARMA CORPORATION v. MODERNATX, INC.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 5,945,416

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.